静脉注射与口服铁剂的临床对比

目的：比较静脉和口服铁剂治疗肾性贫血的疗效与安全性。方法：将本院84例肾性贫血患者分为两组，静脉组注射蔗糖铁，口服组口服琥珀酸亚铁片。两组均应用EP0治疗，比较治疗前及治疗6周、12周后病人血红蛋白（HB）、红细胞（RBC）、红细胞压积（HCT）、血清铁蛋白（SF）及转铁蛋白饱和度（TSAT）的变化情况。结果：治疗结束时，两组患者HB、HCT、RBC、SF及TSAT均较治疗前升高，且静脉注射铁剂组HB、HCT、RBC、SF、TSAT升高水平明显高于口服铁片组（P〈0．05）。结论：静脉用蔗糖铁剂疗效明显优于口服铁剂，且不良反应发生率低，是维持性血液透析患者更为理想的补铁方式。

Intravenous versus oral iron for anemia in 84 patients with chronic renal failure

Objective：To compare the efficacy and safety of intravenous iron sucrose with oral Ferrous Succinate for treatment of renal anemia in patients on maintained hcmodialysis. Methods： Eighty-four patients with renal anemia were divided into 2 groups-the intravenous group and oral group. Patients in both groups received regular EPO. Levels of hemoglobin （HB）, red blood cell （RBC） counts, hemocfit （HCT） , serum ferritin （SF） and transferrin saturation （TSAT） before and at 6, 12 weeks after treatment were compared between the two groups. Results： The levels of HB, HCT, RBC counts, SF and TSAT in both groups after treatment were higher compared with before treatment. The increase appeared greater in intravenous group than in the oral group （P 〈 0.05 ）. Conclusion： Intravenous iron sucrose provided better outcomes and less adverse effects compared with oral iron, and therefore can be an ideal choice for iron supplement in patients on maintained hemodialysis.